Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adjuvant treatment of carcinoma of the oesophagus or the gastroesophageal junction in adults with pathological residual disease after prior neoadjuvant chemoradiotherapy.
Indication of minor added benefit
Press releases
Nivolumab for the adjuvant treatment of esophageal carcinoma: indication of minor added benefit
Project details
- Project no.
- A21-108
- Commission
- Commission awarded on 30.08.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (NSCLC, perioperative) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (unresectable or metastatic urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed